Formosa Laboratories announced on March 18 that its Eribulin Injectable has officially received US FDA Abbreviated New Drug Application (ANDA) approval. This represents the company’s first ANDA, marking a definitive shift from an API supplier to a finished dose player in the US market.

Complex Manufacturing Edge:

Eribulin is a high-potency anticancer agent requiring a staggering 64 synthetic steps and the establishment of 19 chiral centers. Achieving FDA approval underscores Formosa Laboratories's end-to-end capabilities in API synthesis, formulation development, and high-containment manufacturing.

• Market Expansion: While the global Eribulin market is valued at US$370 million, Formosa Laboratories is already expanding into Turkey, Europe, and the Middle East.
• GLP-1 Strategy: Chairman Cheng Cheng-yu revealed that the company is aggressively targeting the GLP-1 sector, specifically Semaglutide (Ozempic/Wegovy). With a combined market exceeding US$30 billion, Formosa Laboratories is preparing mass-production lines for finished injectables to launch immediately upon patent expiry.

Resource: 台耀全球布局報喜！首張ANDA到手 正式叩關美國製劑市場